Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ:TECH) announced the successful results of the AmplideX® PCR/CE SMA Plus Kit from a multisite evaluation study. Published in The Journal of Molecular Diagnostics, the kit showed 98.6% accuracy for SMN1 and 97.1% for SMN2 in diagnosing spinal muscular atrophy (SMA), a condition affecting 1 in 6,000 births. The kit facilitates carrier screening and diagnosis in a streamlined manner, critical for timely treatment. The study involved 468 clinical samples across several international laboratories demonstrating high concordance with established diagnostic methods.
Bio-Techne Corporation (NASDAQ: TECH) has announced a quarterly dividend of $0.32 per share for the period ending March 31, 2021. This dividend will be paid on May 28, 2021 to shareholders recorded by May 17, 2021. The company, a global leader in life sciences, reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. The Board will continue to evaluate future dividends on a quarterly basis.
Bio-Techne Corporation (NASDAQ:TECH) reported strong financial results for Q3 FY2021, with organic revenue growth of 22% to $243.6 million. GAAP EPS increased to $1.12, up from $0.92 last year, while adjusted EPS rose to $1.79 from $1.39. The company achieved a remarkable adjusted operating margin of 40.1%, reflecting effective cost management and higher demand across its segments. Notably, Protein Sciences experienced organic growth of 24%, while Diagnostics and Genomics grew by 17%. Bio-Techne also enhanced its Diagnostics segment through the acquisition of Asuragen.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) announced a collaboration to enhance protein characterization workflows. This partnership combines Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip technology, streamlining the analysis process for biotherapeutics. The integrated solution aims to improve drug development efficiency by providing rapid, high-resolution separation techniques and mass spectrometry identification, catering to the growing biopharmaceutical market.
Bio-Techne Corporation (NASDAQ:TECH) announced the launch of DNAscope Assays, expanding their Advanced Cell Diagnostics RNAscope technology. This new chromogenic DNA in situ hybridization (ISH) technology allows for single-cell resolution to visualize DNA aberrations in FFPE tissues using standard bright-field microscopes. DNAscope provides advantages over traditional FISH techniques, offering precise detection of small genomic regions. Kim Kelderman, President of Diagnostics and Genomics Segment, stated that this launch strengthens their position in spatial genomic analysis, enhancing multi-omic capabilities for faster decision-making.
Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its Pharma Assay Services to Professional Assay Services, aimed at enhancing accessibility for global academic and clinical institutions. The updated services include in situ hybridization (ISH) gene expression analysis, tissue procurement, and custom assay development. Supported by a team of experts, these services comply with Good Clinical Laboratory Practices (GCLP). Kim Kelderman, President of Diagnostics and Genomics, emphasized the commitment to facilitate faster drug development timelines while maintaining cost efficiency.
Bio-Techne Corporation (NASDAQ: TECH) has entered a licensing agreement with Xencor, Inc. for the use of its proprietary antibody in developing innovative cancer therapeutics. This marks Bio-Techne's third collaboration with Xencor, emphasizing their role in the immuno-oncology field. The agreement allows Xencor to utilize Bio-Techne's extensive antibody portfolio alongside its XmAb® protein engineering technology, aimed at creating bispecific antibodies and engineered cytokines. Bio-Techne's commitment to the biopharma industry continues to grow through these strategic partnerships.
Bio-Techne Corporation (NASDAQ:TECH) has launched Abby, an advanced chemiluminescence system designed to automate the traditional Western blotting process. Abby features picogram-level sensitivity and the innovative RePlex™ technology, enabling sequential immunoassays. Additionally, the new Compass software enhances data analysis efficiency. The company also announced the upcoming Stellar™ NIR and IR modules for Jess™, which aim to elevate fluorescence Western blotting sensitivity. Bio-Techne emphasizes that these products contribute to faster, more reproducible results, essential for modern research environments.